• Joyutpal Das, Gagana Mallawaarachchi, Jack Grimshaw, Thomas Jackson, Paul Talbot, Nazar Sharaf, Thaleia Kalatha, Lindsay Lord, Adrian Pace, Tatiana Mihalova, Calvin Heal, and David Rog.
• Cardiovascular Department, The University of Manchester, Manchester, UK joyutpal.das@postgrad.manchester.ac.uk.
• J. Neurol. Neurosurg. Psychiatr. 2024 Jun 5.

BackgroundA growing body of evidence suggests inequitable access to disease-modifying therapies (DMTs) for multiple sclerosis (MS) in publicly funded healthcare systems. This retrospective study examined the impact of ethnicity and deprivation on the access to DMTs.MethodsAll adults diagnosed with relapsing-remitting MS between 2010 and 2020 were included. The impact of ethnicity and deprivation on being offered and starting any DMTs and high-efficacy DMTs were measured using binary, multinomial logistic and Cox regression models. These analyses were adjusted for sex, age at diagnosis and year of diagnosis.Results164/1648 people with MS (PwMS) were from non-white ethnicities. 461/1648 who were living in the most deprived areas, were less likely to be offered DMTs, with an OR of 0.66 (95% CI 0.47 to 0.93), less likely to start high-efficacy DMTs with an OR of 0.67 (95% CI 0.48 to 0.93) and more likely to experience a delay in starting high-efficacy DMTs with an HR of 0.76 (95% CI 0.63 to 0.92), when also adjusted for ethnicity. Although the offer of DMTs did not depend on ethnicity, PwMS from non-white ethnicities were more likely to decline DMTs, less likely to start any DMTs and high-efficacy DMTs with ORs of 0.60 (95% CI 0.39 to 0.93) and 0.61 (95% CI 0.38 to 0.98), respectively, and more likely to experience a delay in starting DMTs with an HR of 0.79 (95% CI 0.66 to 0.95), when also adjusted for deprivation.ConclusionsIn a publicly funded healthcare system, the access to DMTs varied depending on ethnicities and levels of deprivation.© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.

2 keywords...

hide…